Kevin Spencer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kevin Spencer has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Kypros Herodotos Nicolaides
Harris Birthright Research Centre for Fetal Medicine, King's College Hospital London UK
4 shared publications Adolfo W. Liao
Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, Denmark Hill, London SE5 8RX, UK
3 shared publicationsCharas Y. T. Ong
Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, Denmark Hill, London SE5 8RX, UK
3 shared publications- Lut Geerts
Fetal Medicine Unit, Department of Obstetrics and Gynaecology Faculty of Medicine and Health Sciences Stellenbosch University Cape Town South Africa
2 shared publications Adolfo W Liao
Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, Denmark Hill, London SE5 8RX, UK
1 shared publicationCharas Yt Ong
Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, Denmark Hill, London SE5 8RX, UK
1 shared publication
Latest Publications
- 20 June 2002
- Published by Wiley in Prenatal Diagnosis
- Vol. 22 (8) , 656-662
Maternal serum hyperglycosylated human chorionic gonadotrophin (HhCG) in the first trimester of pregnancies affected by Down syndrome, using a sialic acid‐specific lectin immunoassay
In a series of 54 cases of pregnancies complicated by Down syndrome and 224 unaffected pregnancies we examined maternal serum levels of hyperglycosylated human chorionic gonadotrophin (HhCG) in samples collected in the first trimester (11–13 weeks) using a sialic acid‐specific lectin immunoassay. We compared these levels with those of other potential first trimester serum markers [free β‐hCG, pregnancy‐associated plasma protein A (PAPP‐A) and total hCG (ThCG)] and modeled detection rates and false‐positive rates of various biochemical markers in conjunction with fetal nuchal translucency (NT) and maternal age using an maternal age standardized population. Maternal serum HhCG in cases of Down syndrome were significantly elevated (median MoM 1.97) with 24/54 (44%) of cases above the 95th centile for unaffected pregnancies. Free β‐hCG was also elevated (median MoM 2.09) with 33% of cases above the 95th centile. PAPP‐A levels were reduced (median MoM 0.47) with 38% below the 5th centile. ThCG levels, whilst elevated (median MoM 1.34), had only 20% of cases above the 95th centile. Maternal serum HhCG levels were not correlated with fetal NT but showed significant correlation with ThCG and free β‐hCG and with PAPP‐A in the Down syndrome group (r=0.536). Maternal serum HhCG levels in cases with Down syndrome had a significant correlation with gestational age, increasing as the gestation increased. When HhCG was combined together with fetal NT, PAPP‐A and maternal age, at a 5% false‐positive rate the modeled detection rate was 83%, some 6% lower than when free β‐hCG was used and some 4% better than when ThCG was used. Maternal serum HhCG is unlikely to be of additional value when screening for Down syndrome in the first trimester. Copyright © 2002 John Wiley & Sons, Ltd.
- 20 June 2002
- Published by Wiley in Prenatal Diagnosis
- Vol. 22 (8) , 656-662
Maternal serum hyperglycosylated human chorionic gonadotrophin (HhCG) in the first trimester of pregnancies affected by Down syndrome, using a sialic acid‐specific lectin immunoassay
In a series of 54 cases of pregnancies complicated by Down syndrome and 224 unaffected pregnancies we examined maternal serum levels of hyperglycosylated human chorionic gonadotrophin (HhCG) in samples collected in the first trimester (11–13 weeks) using a sialic acid‐specific lectin immunoassay. We compared these levels with those of other potential first trimester serum markers [free β‐hCG, pregnancy‐associated plasma protein A (PAPP‐A) and total hCG (ThCG)] and modeled detection rates and false‐positive rates of various biochemical markers in conjunction with fetal nuchal translucency (NT) and maternal age using an maternal age standardized population. Maternal serum HhCG in cases of Down syndrome were significantly elevated (median MoM 1.97) with 24/54 (44%) of cases above the 95th centile for unaffected pregnancies. Free β‐hCG was also elevated (median MoM 2.09) with 33% of cases above the 95th centile. PAPP‐A levels were reduced (median MoM 0.47) with 38% below the 5th centile. ThCG levels, whilst elevated (median MoM 1.34), had only 20% of cases above the 95th centile. Maternal serum HhCG levels were not correlated with fetal NT but showed significant correlation with ThCG and free β‐hCG and with PAPP‐A in the Down syndrome group (r=0.536). Maternal serum HhCG levels in cases with Down syndrome had a significant correlation with gestational age, increasing as the gestation increased. When HhCG was combined together with fetal NT, PAPP‐A and maternal age, at a 5% false‐positive rate the modeled detection rate was 83%, some 6% lower than when free β‐hCG was used and some 4% better than when ThCG was used. Maternal serum HhCG is unlikely to be of additional value when screening for Down syndrome in the first trimester. Copyright © 2002 John Wiley & Sons, Ltd.
- 12 March 2002
- Published by Wiley in Prenatal Diagnosis
- Vol. 22 (3) , 244-246
Accuracy of Down syndrome risks produced in a first-trimester screening programme incorporating fetal nuchal translucency thickness and maternal serum biochemistry.
- 12 March 2002
- Published by Wiley in Prenatal Diagnosis
- Vol. 22 (3) , 244-246
Accuracy of Down syndrome risks produced in a first-trimester screening programme incorporating fetal nuchal translucency thickness and maternal serum biochemistry.
- 20 August 2001
- Published by Wiley in Prenatal Diagnosis
- Vol. 21 (9) , 718-722
First trimester maternal serum placenta growth factor (PIGF)concentrations in pregnancies with fetal trisomy 21 or trisomy 18
Placenta growth factor (PIGF), an angiogenic factor belonging to the vascular endothelial growth factor family, pregnancy‐associated plasma protein A (PAPP‐A) and free β‐human chorionic gonadotrophin (β‐hCG) were measured in maternal serum from 45 pregnancies with trisomy 21, 45 with trisomy 18 and 493 normal controls at 10–13 completed weeks of gestation. In the normal pregnancies maternal serum PIGF levels increased exponentially with gestation. The median multiple of the median (MoM) PIGF concentration in the trisomy 21 group (1.26 MoM) was significantly higher (pp=0.064). The corresponding median MoM values for PAPP‐A were 1.00 MoM for the controls, 0.49 MoM for trisomy 21 and 0.16 MoM for trisomy 18. The median MoM values for free β‐hCG were 1.00 MoM for the controls, 2.05 MoM for trisomy 21 and 0.38 MoM for trisomy 18. In the control group there was a small but significant correlation of PIGF with free β‐hCG (r=+0.1024) and PAPP‐A (r=+0.2288). In the trisomy 18 group there was a significant association between PIGF and free β‐hCG (r=+0.2629) but not with PAPP‐A (r=+0.0038). In the trisomy 21 group there was a small but significant association with PAPP‐A (r=+0.1028) but not with free β‐hCG (r=+0.0339). The separation of affected and unaffected pregnancies in maternal serum PIGF is small, and therefore it is unlikely that measurement of PIGF would improve screening for these abnormalities provided by the combination of fetal nuchal translucency and maternal serum PAPP‐A and free β‐hCG. Copyright © 2001 John Wiley & Sons, Ltd.
- 20 August 2001
- Published by Wiley in Prenatal Diagnosis
- Vol. 21 (9) , 718-722
First trimester maternal serum placenta growth factor (PIGF)concentrations in pregnancies with fetal trisomy 21 or trisomy 18
Placenta growth factor (PIGF), an angiogenic factor belonging to the vascular endothelial growth factor family, pregnancy‐associated plasma protein A (PAPP‐A) and free β‐human chorionic gonadotrophin (β‐hCG) were measured in maternal serum from 45 pregnancies with trisomy 21, 45 with trisomy 18 and 493 normal controls at 10–13 completed weeks of gestation. In the normal pregnancies maternal serum PIGF levels increased exponentially with gestation. The median multiple of the median (MoM) PIGF concentration in the trisomy 21 group (1.26 MoM) was significantly higher (pp=0.064). The corresponding median MoM values for PAPP‐A were 1.00 MoM for the controls, 0.49 MoM for trisomy 21 and 0.16 MoM for trisomy 18. The median MoM values for free β‐hCG were 1.00 MoM for the controls, 2.05 MoM for trisomy 21 and 0.38 MoM for trisomy 18. In the control group there was a small but significant correlation of PIGF with free β‐hCG (r=+0.1024) and PAPP‐A (r=+0.2288). In the trisomy 18 group there was a significant association between PIGF and free β‐hCG (r=+0.2629) but not with PAPP‐A (r=+0.0038). In the trisomy 21 group there was a small but significant association with PAPP‐A (r=+0.1028) but not with free β‐hCG (r=+0.0339). The separation of affected and unaffected pregnancies in maternal serum PIGF is small, and therefore it is unlikely that measurement of PIGF would improve screening for these abnormalities provided by the combination of fetal nuchal translucency and maternal serum PAPP‐A and free β‐hCG. Copyright © 2001 John Wiley & Sons, Ltd.
- 20 August 2001
- Published by Wiley in Prenatal Diagnosis
- Vol. 21 (9) , 715-717
Screening for trisomy 21 in twin pregnancies in the first trimester: does chorionicity impact on maternal serum free β‐hCG or PAPP‐A levels?
In a study of 180 twin pregnancies I have examined the distribution of maternal serum free β‐human chorionic gonadotrophin (β‐hCG) and pregnancy‐associated plasma protein‐A (PAPP‐A), in addition to fetal nuchal translucency thickness (NT), in twins classified as monochorionic or dichorionic, based on ultrasound appearance at 10–14 weeks of gestation. In 45 monochorionic and 135 dichorionic twin pregnancies the median MoM free β‐hCG was not significantly different (1.00 vs 1.01), whilst that for PAPP‐A was lower (0.89 vs 1.01) but again with no statistical significance. Previous reports of an increased fetal NT in monochorionic twins pregnancies could not be confirmed (1.03 vs 1.00). It is concluded that the existing pseudo risk twin correction algorithm is appropriate for both monochorionic and dichorionic twins in providing accurate first trimester risks for trisomy 21. Copyright © 2001 John Wiley & Sons, Ltd.
- 20 August 2001
- Published by Wiley in Prenatal Diagnosis
- Vol. 21 (9) , 715-717
Screening for trisomy 21 in twin pregnancies in the first trimester: does chorionicity impact on maternal serum free β‐hCG or PAPP‐A levels?
In a study of 180 twin pregnancies I have examined the distribution of maternal serum free β‐human chorionic gonadotrophin (β‐hCG) and pregnancy‐associated plasma protein‐A (PAPP‐A), in addition to fetal nuchal translucency thickness (NT), in twins classified as monochorionic or dichorionic, based on ultrasound appearance at 10–14 weeks of gestation. In 45 monochorionic and 135 dichorionic twin pregnancies the median MoM free β‐hCG was not significantly different (1.00 vs 1.01), whilst that for PAPP‐A was lower (0.89 vs 1.01) but again with no statistical significance. Previous reports of an increased fetal NT in monochorionic twins pregnancies could not be confirmed (1.03 vs 1.00). It is concluded that the existing pseudo risk twin correction algorithm is appropriate for both monochorionic and dichorionic twins in providing accurate first trimester risks for trisomy 21. Copyright © 2001 John Wiley & Sons, Ltd.
- 3 July 2001
- Published by Wiley in Prenatal Diagnosis
- Vol. 21 (7) , 571-574
Maternal serum activin A and inhibin A in trisomy 18 pregnancies at 10–14 weeks
In 45 cases of trisomy 18 and 493 control pregnancies at 10–14 weeks of gestation, maternal serum inhibin A, total activin A, free β-hCG and PAPP-A were measured. In the trisomy 18 pregnancies the median values were 0.74 MoM for inhibin A, 1.23 MoM for activin A, 0.38 MoM for free β-hCG and 0.16 MoM for PAPP-A. The degree of deviation from normal in the levels of inhibin and activin is small in comparison with free β-hCG and PAPP-A and they are therefore unlikely to be of value in improving the sensitivity of 90% for a 1% false-positive rate achieved by screening with fetal nuchal translucency and maternal serum free β-hCG and PAPP-A. Copyright © 2001 John Wiley & Sons, Ltd.
- 3 July 2001
- Published by Wiley in Prenatal Diagnosis
- Vol. 21 (7) , 571-574
Maternal serum activin A and inhibin A in trisomy 18 pregnancies at 10–14 weeks
In 45 cases of trisomy 18 and 493 control pregnancies at 10–14 weeks of gestation, maternal serum inhibin A, total activin A, free β-hCG and PAPP-A were measured. In the trisomy 18 pregnancies the median values were 0.74 MoM for inhibin A, 1.23 MoM for activin A, 0.38 MoM for free β-hCG and 0.16 MoM for PAPP-A. The degree of deviation from normal in the levels of inhibin and activin is small in comparison with free β-hCG and PAPP-A and they are therefore unlikely to be of value in improving the sensitivity of 90% for a 1% false-positive rate achieved by screening with fetal nuchal translucency and maternal serum free β-hCG and PAPP-A. Copyright © 2001 John Wiley & Sons, Ltd.
- 18 May 2001
- Published by Wiley in Prenatal Diagnosis
- Vol. 21 (6) , 445-447
Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies
In a group of 149 women who had undergone routine first trimester screening using fetal nuchal translucency thickness (NT) and maternal serum free β-hCG and pregnancy associated plasma protein-A (PAPP-A) in two consecutive pregnancies the within person between pregnancy biological variability of these markers has been assessed. For fetal NT there was no correlation between NT MoM in the first and second pregnancy (r=0.0800). For maternal serum free β-hCG MoM a significant correlation was observed (r=0.4174) as was also found for PAPP-A MoM (r=0.3270). The implications for such between pregnancy marker association is that women who have an increased risk of Down syndrome in their first pregnancy are 1.5–2 times more likely to repeat this event in their next pregnancy. This observation may be useful in counselling women in the first trimester screening of a subsequent pregnancy. Copyright © 2001 John Wiley & Sons, Ltd.
- 18 May 2001
- Published by Wiley in Prenatal Diagnosis
- Vol. 21 (6) , 445-447
Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies
In a group of 149 women who had undergone routine first trimester screening using fetal nuchal translucency thickness (NT) and maternal serum free β-hCG and pregnancy associated plasma protein-A (PAPP-A) in two consecutive pregnancies the within person between pregnancy biological variability of these markers has been assessed. For fetal NT there was no correlation between NT MoM in the first and second pregnancy (r=0.0800). For maternal serum free β-hCG MoM a significant correlation was observed (r=0.4174) as was also found for PAPP-A MoM (r=0.3270). The implications for such between pregnancy marker association is that women who have an increased risk of Down syndrome in their first pregnancy are 1.5–2 times more likely to repeat this event in their next pregnancy. This observation may be useful in counselling women in the first trimester screening of a subsequent pregnancy. Copyright © 2001 John Wiley & Sons, Ltd.
- 18 May 2001
- Published by Wiley in Prenatal Diagnosis
- Vol. 21 (6) , 441-444
Maternal serum levels of dimeric inhibin A in pregnancies affected by trisomy 21 in the first trimester
Dimeric inhibin A was measured in maternal serum samples from 45 pregnancies affected by trisomy 21 and 493 samples from unaffected pregnancies at 10–14 weeks of gestation. Inhibin A levels in affected pregnancies were compared with levels of free β‐hCG and PAPP‐A in the same series. In the trisomy 21 group, the median multiple of the median (MoM) inhibin A was not significantly elevated (1.28 vs 1.00) with only 15.5% being above the 95th centile. In contrast, the median MoM free β‐hCG was significantly increased (2.05 vs 1.00) with 36% above the 95th centile and PAPP‐A was significantly reduced (0.49 vs 1.00) with 42% below the 5th centile. Inhibin A levels in the trisomy 21 group were significantly correlated with gestational age such that median levels rose from 1.04 at 11 weeks to 1.30 at 12 weeks and 1.67 at 13 weeks. These findings suggest that first trimester biochemical screening for trisomy 21, which is currently optimised using maternal serum free β‐hCG and PAPP‐A and fetal nuchal translucency, will not benefit from the inclusion of inhibin A. Copyright © 2001 John Wiley & Sons, Ltd.
- 18 May 2001
- Published by Wiley in Prenatal Diagnosis
- Vol. 21 (6) , 441-444
Maternal serum levels of dimeric inhibin A in pregnancies affected by trisomy 21 in the first trimester
Dimeric inhibin A was measured in maternal serum samples from 45 pregnancies affected by trisomy 21 and 493 samples from unaffected pregnancies at 10–14 weeks of gestation. Inhibin A levels in affected pregnancies were compared with levels of free β‐hCG and PAPP‐A in the same series. In the trisomy 21 group, the median multiple of the median (MoM) inhibin A was not significantly elevated (1.28 vs 1.00) with only 15.5% being above the 95th centile. In contrast, the median MoM free β‐hCG was significantly increased (2.05 vs 1.00) with 36% above the 95th centile and PAPP‐A was significantly reduced (0.49 vs 1.00) with 42% below the 5th centile. Inhibin A levels in the trisomy 21 group were significantly correlated with gestational age such that median levels rose from 1.04 at 11 weeks to 1.30 at 12 weeks and 1.67 at 13 weeks. These findings suggest that first trimester biochemical screening for trisomy 21, which is currently optimised using maternal serum free β‐hCG and PAPP‐A and fetal nuchal translucency, will not benefit from the inclusion of inhibin A. Copyright © 2001 John Wiley & Sons, Ltd.
- 27 February 2001
- Published by Wiley in Prenatal Diagnosis
- Vol. 21 (4) , 270-273
Maternal serum levels of total activin‐A in first‐trimester trisomy 21 pregnancies
Maternal serum total activin‐A concentration was measured in 45 pregnancies affected by trisomy 21 and 493 control unaffected pregnancies at 10–14 weeks of gestation. In the trisomy 21 pregnancies total activin‐A concentration was significantly higher (1.36 MoM of the unaffected pregnancies) and in 16% of cases the level was above the 95th centile of normal. The log10 SD for the control group and the trisomy 21 group were 0.17 and 0.22, respectively. The median pregnancy associated plasma protein‐A (PAPP‐A) in this trisomy 21 series was 0.49 and for free β‐hCG was 2.05. In the trisomy group there were significant positive associations between total activin‐A and PAPP‐A (0.6071) and free β‐hCG (0.4255). The low median difference and the high overlap in values between trisomic and unaffected pregnancies make total activin‐A of little practical use in first‐trimester screening for trisomy 21. Copyright © 2001 John Wiley & Sons, Ltd.
- 27 February 2001
- Published by Wiley in Prenatal Diagnosis
- Vol. 21 (4) , 270-273
Maternal serum levels of total activin‐A in first‐trimester trisomy 21 pregnancies
Maternal serum total activin‐A concentration was measured in 45 pregnancies affected by trisomy 21 and 493 control unaffected pregnancies at 10–14 weeks of gestation. In the trisomy 21 pregnancies total activin‐A concentration was significantly higher (1.36 MoM of the unaffected pregnancies) and in 16% of cases the level was above the 95th centile of normal. The log10 SD for the control group and the trisomy 21 group were 0.17 and 0.22, respectively. The median pregnancy associated plasma protein‐A (PAPP‐A) in this trisomy 21 series was 0.49 and for free β‐hCG was 2.05. In the trisomy group there were significant positive associations between total activin‐A and PAPP‐A (0.6071) and free β‐hCG (0.4255). The low median difference and the high overlap in values between trisomic and unaffected pregnancies make total activin‐A of little practical use in first‐trimester screening for trisomy 21. Copyright © 2001 John Wiley & Sons, Ltd.